Geranylgeranylacetone decreases the production of hepatitis B virus-related antigen by comprehensive downregulation of mRNA transcription activity.

Masafumi HaraguchiSatoshi MiumaKazuo YamamotoYasuhiko NakaoTatsuki IchikawaYasuko KandaRyu SasakiMasanori FukushimaYuko AkazawaHisamitsu MiyaakiKazuhiko Nakao

Published in: Journal of gastroenterology and hepatology (2021)

Geranylgeranylacetone treatment reduces HBV-related protein levels by suppressing comprehensive downregulation of HBV promoter and enhancer activity, which might be caused by decreased hepatic transcription factor expression. GGA treatment may enhance anti-HBV effects in combination with other therapies.

Keyphrases

hepatitis b virus
transcription factor
liver failure
cell proliferation
dna methylation
binding protein
poor prognosis
signaling pathway
long non coding rna
genome wide identification